Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,264 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pathways Clear all
Completed Not applicable Interventional

Physiological Changes Induced Through MEP Conditioning in People With SCI

NCT04286191
View directory record Official record
Conditions
Spinal Cord Injuries, Neurological Injury, Paralysis, Spasticity, Muscle
Interventions
Operant Conditioning, Control Group
Combination Product
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 18, 2026, 1:50 AM EDT
Terminated Not applicable Interventional

Hypotonia and Neurofibromatosis Type 1 (NF1) Glioma

NCT02584413
View directory record Official record
Conditions
Neurofibromatosis Type 1
Interventions
Magnetic resonance imaging, Gadolinium contrast
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Year to 7 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Oct 18, 2026, 1:50 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway

NCT06320951
View directory record Official record
Conditions
Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease, Metabolism, Energy Expenditure, Obesity
Interventions
Vericiguat 10 MG, Placebo, Insulin Sensitivity Test, Resting Energy and Exercise Energy Expenditure Assessment, White Adipose Tissue Biopsy, MRI-PET Scan for Brown Adipose Tissue Volume Assessment
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 18, 2026, 1:50 AM EDT
Not listed No phase listed Observational

DyeVert™ System for Contrast Monitoring in At-Risk Patients Undergoing Angiography: A Real-World Registry

NCT03825094
View directory record Official record
Conditions
Patients at Risk for Developing Contrast-induced Nephropathy
Interventions
DyeVert™ Contrast Reduction Systems
Device
Lead sponsor
Osprey Medical, Inc
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
Hartford, Connecticut • Hialeah, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 18, 2026, 1:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

NCT07206056
View directory record Official record
Conditions
Progressive Metastatic Castrate Resistant Prostate Cancer
Interventions
Tulmimetostat DL1 QD, Tulmimetostat DL2 QD, Tulmimetostat DL3 QD, Tulmimetostat Doses 1 or 2 QD, Tulmimetostat RP2D QD, JSB462 Dose 1 QD, JSB462 Dose 2 QD, JSB462 QD, Standard of Care (SoC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
8
States / cities
Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 18, 2026, 1:50 AM EDT
Not listed Not applicable Interventional

Resistance Training in Type 1 Diabetes Mellitus

NCT05315037
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Resistance Training
Other
Lead sponsor
University of Louisville
Other
Eligibility
13 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma

NCT01967576
View directory record Official record
Conditions
Pheochromocytoma, Paraganglioma
Interventions
Axitinib (AG-013736)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 18, 2026, 1:50 AM EDT
Recruiting Phase 1 Interventional

Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors

NCT07095517
View directory record Official record
Conditions
Colorectal Cancer Prevention, Colorectal Adenoma
Interventions
Tirzepatide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 18, 2026, 1:50 AM EDT
Recruiting Phase 1 Interventional

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

NCT07103018
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients, Metastatic Castration-resistant Prostate Cancer, mCRPC, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer)
Interventions
KTX-2001, KTX-2001 + Darolutamide (NUBEQA®)
Drug
Lead sponsor
K36 Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
San Francisco, California • Miami, Florida • Port Saint Lucie, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 18, 2026, 1:50 AM EDT
Recruiting Not applicable Interventional

The Geriatric Emergency Department Pharmacologic Harm Prevention Project

NCT07216846
View directory record Official record
Conditions
Fall, Fall Accident, Poly Pharmacy, Adverse Drug Events, Pharmacogenomic Drug Interaction, Pharmacogenomic Testing
Interventions
DNA care pathway
Other
Lead sponsor
Florida Atlantic University
Other
Eligibility
65 Years to 110 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Delray Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 18, 2026, 1:50 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The Contributions of Age Related Changes in the Sound Localization Pathway to Central Hearing Loss

NCT04513782
View directory record Official record
Conditions
Healthy Individuals, Hearing Loss, Central
Interventions
Audiological Assessments
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 1 Interventional

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

NCT03434262
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
Interventions
Gemcitabine, ribociclib, sonidegib, trametinib, filgrastim
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 39 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Determination of Pre-Absorptive Dissociation of Zinc From a Zinc Amino Acid Complex in Healthy Men

NCT03934346
View directory record Official record
Conditions
Fractional Zinc Absorption
Interventions
Zinc amino acid complex
Other
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 18, 2026, 1:50 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

NCT02503423
View directory record Official record
Conditions
Solid Tumors, Lymphoma
Interventions
ASTX660
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
31
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 3 Interventional Results available

Patient-Reported Outcomes in Evaluating Lorecivivint (SM04690) for Moderate to Severe Knee Osteoarthritis (STRIDES-1)

NCT04385303
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Lorecivivint, Placebo
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
76
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 1 Interventional

Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling

NCT01217359
View directory record Official record
Conditions
Hepatitis C
Interventions
Interferon Alfa-2b
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Oct 18, 2026, 1:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

Pathways 2 Success

NCT06831123
View directory record Official record
Conditions
Conduct Disorder, Oppositional Defiant Disorder
Interventions
L2B, L2B + App, skills for success
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
13 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 1 Interventional

Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors

NCT01172028
View directory record Official record
Conditions
Breast Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions
Taxotere (Docetaxel), Alimta (Pemetrexed)
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 1 Interventional Results available

KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia

NCT04914845
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Interventions
KPT-9274
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 18, 2026, 1:50 AM EDT
Recruiting Not applicable Interventional

Multisite Transspinal Stimulation for Augmenting Recovery in Spinal Cord Injury

NCT07204184
View directory record Official record
Conditions
Spinal Cord Injuries (Complete and Incomplete)
Interventions
Multisite transspinal stimulation at rest, Multisite transspinal stimulation during robotic gait training
Device
Lead sponsor
Maria Knikou, PT, MBA, PhD
Other
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 18, 2026, 1:50 AM EDT
Recruiting No phase listed Observational

University of Michigan "Nephrology Research BioBank"

NCT00381121
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2030
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Neurobiology of Expectancy and Pain Perception

NCT01575106
View directory record Official record
Conditions
Pain
Interventions
Heat pain applied using TSA or CHEPS
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 50 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 18, 2026, 1:50 AM EDT
Terminated Phase 3 Interventional Results available

Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer

NCT01132547
View directory record Official record
Conditions
Cancer
Interventions
cyproheptadine hydrochloride, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
14
States / cities
Long Beach, California • Hartford, Connecticut • Wilmington, Delaware + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Oct 18, 2026, 1:50 AM EDT
Recruiting Phase 2 Interventional

Ulixertinib in People With Histiocytic Neoplasms

NCT06411821
View directory record Official record
Conditions
Histiocytic Neoplasms
Interventions
Ulixertinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Rochester, Minnesota • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 18, 2026, 1:50 AM EDT